Product Description
Fosnetupitant is the prodrug of [netupitant]. Netupitant is a moderate inhibitor and substrate of CYP3A4. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Fosnetupitant#section=Absorption-Distribution-and-Excretion)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Japan | Netherlands | Spain | United States
Approved Indications: None
Known Adverse Events: None
Company: Helsinn Healthcare
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Greece, Poland, Romania, Turkey
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Nose Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Part II, Repeated Cycles | P2 |
Not yet recruiting |
Nose Cancer |
2027-10-01 |